

PORTEC-2: Post-Operative Radiation Therapy for Endometrial Carcinoma - a multicentre randomised phase III trial comparing external beam radiation and vaginal brachytherapy

Submission date 20/12/2005	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 20/12/2005	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
Last Edited 14/02/2020	Condition category Cancer	<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr C.L. Creutzberg

Contact details
Leiden University Medical Centre
Department of Clinical Oncology
P.O. Box 9600
Leiden
Netherlands
2300 RC
+31 (0)71 526 3027
c.l.creutzberg@lumc.nl

Additional identifiers

ClinicalTrials.gov (NCT)
NCT00376844

Protocol serial number
NTR332; CKTO 2001-04; LUMC P01.146

Study information

Scientific Title

PORTEC-2: Post-Operative Radiation Therapy for Endometrial Carcinoma - a multicentre randomised phase III trial comparing external beam radiation and vaginal brachytherapy

Acronym

PORTEC-2

Study objectives

Vaginal brachytherapy, as compared to external beam pelvic radiotherapy, will provide equal 5-year vaginal control and overall survival, with less treatment related morbidity and better quality of life.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Received from the local medical ethics committee

Primary study design

Interventional

Study design

Multicentre, randomised, active controlled, parallel group trial

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Endometrial carcinoma

Interventions

Patients are randomised to receive external beam pelvic radiotherapy (standard arm: 46 Gy in 2 Gy fractions in 5 weeks) or vaginal brachytherapy (study arm: HDR 21 Gy in 3 fractions of 7 Gy, each 1 week apart; or MDR 28 Gy in one session; or LDR 30 Gy in one session).

Intervention Type

Other

Phase

Not Specified

Primary outcome(s)

5-year actuarial vaginal relapse

Key secondary outcome(s)

1. 5-year overall survival and cancer-specific survival
2. Quality of life and treatment related morbidity

3. 5-year rates of pelvic and distant relapse
4. Local control and survival after relapse

Completion date

01/09/2006

Eligibility

Key inclusion criteria

1. Endometrial carcinoma, with one of the following combinations of postoperative FIGO stage and age:
 - 1.1. Stage 1C grade 1 or 2 and age 60 or over
 - 1.2. Stage 1B grade 3 and age 60 or over
 - 1.3. Stage 2A, any age, grade 1 or 2
 - 1.4. Stage 2A, any age, grade 3 with less than half myometrial invasion
2. Surgery consisted of a total abdominal hysterectomy and bilateral salpingo-oophorectomy (TAH-BSO)
3. Histologically proven adenocarcinoma; grade of differentiation determined according to the Federation of Obstetricians and Gynaecologists (FIGO)/Armed Forces Institute of Pathology (AFIP) criteria; depth of myometrial invasion documented
4. World Health Organization (WHO) performance status 0 - 2
5. Written informed consent

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Senior

Sex

Female

Total final enrolment

427

Key exclusion criteria

1. One of the following combinations of FIGO stage and age:
 - 1.1. Stage 2B, 3 or 4
 - 1.2. Stage 2A and grade 3 with 50% or greater myometrial invasion
 - 1.3. Stage IA or IB grade 1 or 2
 - 1.4. Stage 1B grade 3 and age below 60
 - 1.5. Stage 1C grade 1 or 2 and age below 60
 - 1.6. Stage IC grade 3, any age
2. Histological subtypes papillary serous carcinoma or clear cell carcinoma
3. Routine staging lymphadenectomy
4. Interval between the operation and start of radiotherapy exceeding 8 weeks
5. History of any previous malignancy, except for basal cell carcinoma of the skin

6. Previous pelvic radiotherapy
7. Hormonal therapy or chemotherapy for this tumour
8. Prior diagnosis of Crohn's disease or ulcerative colitis

Date of first enrolment

01/06/2002

Date of final enrolment

01/09/2006

Locations

Countries of recruitment

Netherlands

Study participating centre

Leiden University Medical Centre

Leiden

Netherlands

2300 RC

Sponsor information

Organisation

Leiden University Medical Centre (LUMC) (Netherlands)

ROR

<https://ror.org/027bh9e22>

Funder(s)

Funder type

Charity

Funder Name

KWF Kankerbestrijding

Alternative Name(s)

Dutch Cancer Society, Dutch Cancer Society (KWF Kankerbestrijding), KWF, DCS

Funding Body Type

Private sector organisation

Funding Body Subtype

Other non-profit organizations

Location

Netherlands

Funder Name

Commission for Medical Applied Research (Commissie voor Klinisch Toegepast Onderzoek [CKTO]) (Netherlands)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	20/07/2009		Yes	No
Results article	results	06/03/2010		Yes	No
Results article	results	01/07/2012		Yes	No
Results article	results	15/11/2015	14/02/2020	Yes	No
Study website	Study website	11/11/2025	11/11/2025	No	Yes